MERS-CoV Standards, Assays and Animal Models for Vaccine Development

[1]  B. Bosch,et al.  Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections , 2019, Emerging infectious diseases.

[2]  M. Müller,et al.  Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus , 2019, Emerging infectious diseases.

[3]  D. Weiner,et al.  Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial , 2019, The Lancet Infectious Diseases.

[4]  Simon Cauchemez,et al.  Comparative Analysis of Eleven Healthcare-Associated Outbreaks of Middle East Respiratory Syndrome Coronavirus (Mers-Cov) from 2015 to 2017 , 2019, Scientific Reports.

[5]  S. Cauchemez,et al.  Comparative Analysis of Eleven Healthcare-Associated Outbreaks of Middle East Respiratory Syndrome Coronavirus (Mers-Cov) from 2015 to 2017 , 2019, Scientific Reports.

[6]  T. Bestebroer,et al.  Lack of Middle East Respiratory Syndrome Coronavirus Transmission in Rabbits , 2019, Viruses.

[7]  B. Haagmans,et al.  Host Determinants of MERS-CoV Transmission and Pathogenesis , 2019, Viruses.

[8]  N. Petrovsky,et al.  Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas , 2019, Viruses.

[9]  Gheyath K Nasrallah,et al.  Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar , 2019, Journal of immunology research.

[10]  A. Nalca,et al.  African green monkey model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection , 2019, International Journal of Infectious Diseases.

[11]  Linqi Zhang,et al.  Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection , 2019, Emerging microbes & infections.

[12]  M. V. Van Kerkhove,et al.  An updated roadmap for MERS-CoV research and product development: focus on diagnostics , 2019, BMJ Global Health.

[13]  F. Grosveld,et al.  Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein , 2019, Emerging microbes & infections.

[14]  M. Letko,et al.  Bactrian camels shed large quantities of Middle East respiratory syndrome coronavirus (MERS-CoV) after experimental infection , 2019, Emerging microbes & infections.

[15]  E. Gardner,et al.  Detection of distinct MERS-Coronavirus strains in dromedary camels from Kenya, 2017 , 2018, Emerging Microbes & Infections.

[16]  O. Engelhardt,et al.  Establishment of the first WHO International Standard for antiserum to Respiratory Syncytial Virus: Report of an international collaborative study , 2018, Vaccine.

[17]  M. Müller,et al.  Challenges of Convalescent Plasma Infusion Therapy in Middle East Respiratory Coronavirus Infection: A Single Centre Experience , 2018, Antiviral therapy.

[18]  A. Pollard,et al.  Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG , 2018, Biologicals : journal of the International Association of Biological Standardization.

[19]  Piers Millett,et al.  World Health Organization Methodology to Prioritize Emerging Infectious Diseases in Need of Research and Development , 2018, Emerging infectious diseases.

[20]  Nam-Hyuk Cho,et al.  Development of a diagnostic system for detection of specific antibodies and antigens against Middle East respiratory syndrome coronavirus , 2018, Microbiology and immunology.

[21]  Shibo Jiang,et al.  Prospects for a MERS-CoV spike vaccine , 2018, Expert review of vaccines.

[22]  R. Baric,et al.  Modeling pathogenesis of emergent and pre-emergent human coronaviruses in mice , 2018, Mammalian Genome.

[23]  J. Segalés,et al.  Experimental infection of dromedaries with Middle East respiratory syndrome-Coronavirus is accompanied by massive ciliary loss and depletion of the cell surface receptor dipeptidyl peptidase 4 , 2018, Scientific Reports.

[24]  Steffen Prüfer,et al.  Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model , 2018, Virology.

[25]  J. Chan,et al.  Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells , 2018, The Journal of Biological Chemistry.

[26]  J. Al-Tawfiq,et al.  Healthcare-associated infections: the hallmark of Middle East respiratory syndrome coronavirus with review of the literature , 2018, Journal of Hospital Infection.

[27]  L. Bao,et al.  The battle against SARS and MERS coronaviruses: Reservoirs and Animal Models , 2018, Animal models and experimental medicine.

[28]  K. Kang,et al.  Heterologous prime–boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus , 2018, Vaccine.

[29]  Lisa E. Gralinski,et al.  Combination Attenuation Offers Strategy for Live Attenuated Coronavirus Vaccines , 2018, Journal of Virology.

[30]  Z. Memish,et al.  Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission , 2018, The Lancet Infectious Diseases.

[31]  Wenling Wang,et al.  Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus , 2018, Emerging Microbes & Infections.

[32]  S. Khurana,et al.  What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection. , 2018, Cold Spring Harbor perspectives in biology.

[33]  R. Webby,et al.  MERS coronaviruses from camels in Africa exhibit region-dependent genetic diversity , 2018, Proceedings of the National Academy of Sciences.

[34]  V. Corman,et al.  Hosts and Sources of Endemic Human Coronaviruses , 2018, Advances in Virus Research.

[35]  Z. Bu,et al.  A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization , 2017, Antiviral Research.

[36]  G. Olinger,et al.  Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies , 2017, Drugs.

[37]  V. Munster,et al.  Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model , 2017, npj Vaccines.

[38]  M. Tortorici,et al.  Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein , 2017, Proceedings of the National Academy of Sciences.

[39]  Lisa E. Gralinski,et al.  MERS-CoV Accessory ORFs Play Key Role for Infection and Pathogenesis , 2017, mBio.

[40]  Barney S. Graham,et al.  Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen , 2017, Proceedings of the National Academy of Sciences.

[41]  P. T. Ten Eyck,et al.  Recovery from the Middle East respiratory syndrome is associated with antibody and T cell responses , 2017, Science Immunology.

[42]  K. Subbarao,et al.  Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody , 2017, PLoS pathogens.

[43]  G. Mattiuzzo,et al.  Developing biological standards for vaccine evaluation , 2017 .

[44]  S. H. Kim,et al.  Suggested new breakpoints of anti-MERS-CoV antibody ELISA titers: performance analysis of serologic tests , 2017, European Journal of Clinical Microbiology & Infectious Diseases.

[45]  A. Hill,et al.  ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice , 2017, Vaccine.

[46]  Yufei Wang,et al.  Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection , 2017, Human vaccines & immunotherapeutics.

[47]  Jincun Zhao,et al.  DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice , 2017, Vaccine.

[48]  J. Segalés,et al.  Searching for animal models and potential target species for emerging pathogens: Experience gained from Middle East respiratory syndrome (MERS) coronavirus , 2017, One Health.

[49]  L. Bao,et al.  Comparative pathology of rhesus macaque and common marmoset animal models with Middle East respiratory syndrome coronavirus , 2017, PloS one.

[50]  M. Frieman,et al.  MERS-CoV spike nanoparticles protect mice from MERS-CoV infection , 2017, Vaccine.

[51]  J. Segalés,et al.  Livestock Susceptibility to Infection with Middle East Respiratory Syndrome Coronavirus , 2017, Emerging infectious diseases.

[52]  Lu Lu,et al.  MERS-CoV spike protein: a key target for antivirals , 2017, Expert opinion on therapeutic targets.

[53]  Bart L. Haagmans,et al.  MERS-coronavirus: From discovery to intervention , 2016, One Health.

[54]  Arun Srivastava,et al.  In vivo tissue-tropism of adeno-associated viral vectors. , 2016, Current opinion in virology.

[55]  B. Meyer,et al.  Time Course of MERS-CoV Infection and Immunity in Dromedary Camels , 2016, Emerging infectious diseases.

[56]  R. Baric,et al.  A mouse model for MERS coronavirus-induced acute respiratory distress syndrome , 2016, Nature Microbiology.

[57]  G. Gao,et al.  The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection , 2016, Vaccine.

[58]  P. Jahrling,et al.  One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus , 2016, Journal of Virology.

[59]  Yufei Wang,et al.  A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection , 2016, Virology.

[60]  T. E. Tandi,et al.  Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications , 2016, Journal of Hospital Infection.

[61]  F. Hayden,et al.  Emerging Blockininfectious Blockindiseases Blockin@bullet Blockin Feasibility of Using Convalescent Plasma Immunotherapy for Mers-cov Infection, Saudi Arabia , 2022 .

[62]  D. Beasley,et al.  First vaccine approval under the FDA Animal Rule , 2016, npj Vaccines.

[63]  V. Brown,et al.  Inoculation of Goats, Sheep, and Horses with MERS-CoV Does Not Result in Productive Viral Shedding , 2016, Viruses.

[64]  Jerome H. Kim,et al.  A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation , 2016, Nature Medicine.

[65]  C. Midgley,et al.  Epidemiology of a Novel Recombinant Middle East Respiratory Syndrome Coronavirus in Humans in Saudi Arabia , 2016, The Journal of infectious diseases.

[66]  Krishna Shankara Narayanan,et al.  Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus , 2016, Human vaccines & immunotherapeutics.

[67]  M. Peiris,et al.  Experimental Infection and Response to Rechallenge of Alpacas with Middle East Respiratory Syndrome Coronavirus , 2016, Emerging infectious diseases.

[68]  Hualei Wang,et al.  MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques , 2016, Oncotarget.

[69]  H. Feldmann,et al.  An Acute Immune Response to Middle East Respiratory Syndrome Coronavirus Replication Contributes to Viral Pathogenicity , 2016, The American Journal of Pathology.

[70]  I. Khalid,et al.  Acute Management and Long-Term Survival Among Subjects With Severe Middle East Respiratory Syndrome Coronavirus Pneumonia and ARDS , 2016, Respiratory Care.

[71]  G. Olinger,et al.  Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo , 2016, Science Translational Medicine.

[72]  Alimuddin Zumla,et al.  Coronaviruses — drug discovery and therapeutic options , 2016, Nature Reviews Drug Discovery.

[73]  H. Feldmann,et al.  A Comparative Review of Animal Models of Middle East Respiratory Syndrome Coronavirus Infection , 2016, Veterinary pathology.

[74]  A. Cheng,et al.  The epidemiology of Middle East respiratory syndrome coronavirus in the Kingdom of Saudi Arabia, 2012–2015 , 2016, International Journal of Infectious Diseases.

[75]  Ulas Bagci,et al.  3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012 , 2016, Virology.

[76]  J. Segalés,et al.  An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels , 2016, Science.

[77]  David K. Smith,et al.  Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia , 2016, Science.

[78]  F. Polack,et al.  Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease , 2015, Clinical and Vaccine Immunology.

[79]  E. Won,et al.  Combination Therapy with Lopinavir/Ritonavir, Ribavirin and Interferon-α for Middle East Respiratory Syndrome , 2015, Antiviral therapy.

[80]  David K Meyerholz,et al.  Middle East Respiratory Syndrome Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4 , 2015, The Journal of infectious diseases.

[81]  L. Poon,et al.  Comparison of serological assays in human Middle East respiratory syndrome (MERS)-coronavirus infection. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[82]  H. Eldin,et al.  A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform , 2015, Journal of Virology.

[83]  Joshua C. Johnson,et al.  Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease , 2015, Virology.

[84]  N. Sardesai,et al.  A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates , 2015, Science Translational Medicine.

[85]  G. Gao,et al.  Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge , 2015, EBioMedicine.

[86]  Malik Peiris,et al.  Middle East respiratory syndrome , 2015, The Lancet.

[87]  Ulas Bagci,et al.  Evaluation of candidate vaccine approaches for MERS-CoV , 2015, Nature Communications.

[88]  V. Munster,et al.  Animal models of Middle East respiratory syndrome coronavirus infection , 2015, Antiviral Research.

[89]  G. Yancopoulos,et al.  Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection , 2015, Proceedings of the National Academy of Sciences.

[90]  G. Sutter,et al.  Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein , 2015, Journal of Virology.

[91]  F. Farahat,et al.  IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study , 2015, The Journal of antimicrobial chemotherapy.

[92]  W. Tan,et al.  Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus , 2015, Immunology.

[93]  Shibo Jiang,et al.  Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus , 2015, Human vaccines & immunotherapeutics.

[94]  Victor M Corman,et al.  Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study , 2015, The Lancet Infectious Diseases.

[95]  T. Kuiken,et al.  Asymptomatic Middle East Respiratory Syndrome Coronavirus Infection in Rabbits , 2015, Journal of Virology.

[96]  S. Perlman,et al.  Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus , 2015, Cellular and Molecular Immunology.

[97]  R. Couch,et al.  Generation of a Transgenic Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease , 2015, Journal of Virology.

[98]  M. Koopmans,et al.  High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014 , 2015, Infection ecology & epidemiology.

[99]  B. Bosch,et al.  MERS Coronavirus Neutralizing Antibodies in Camels, Eastern Africa, 1983–1997 , 2014, Emerging infectious diseases.

[100]  V. Brown,et al.  Replication and Shedding of MERS-CoV in Upper Respiratory Tract of Inoculated Dromedary Camels , 2014, Emerging infectious diseases.

[101]  G. Gao,et al.  Tailoring Subunit Vaccine Immunity with Adjuvant Combinations and Delivery Routes Using the Middle East Respiratory Coronavirus (MERS-CoV) Receptor-Binding Domain as an Antigen , 2014, PloS one.

[102]  Z. Memish,et al.  Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study , 2014, The Lancet Infectious Diseases.

[103]  Shibo Jiang,et al.  Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design , 2014, Vaccine.

[104]  A. Gambotto,et al.  Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice , 2014, Vaccine.

[105]  Xinxia Peng,et al.  Infection with MERS-CoV Causes Lethal Pneumonia in the Common Marmoset , 2014, PLoS pathogens.

[106]  B. Bosch,et al.  Geographic Distribution of MERS Coronavirus among Dromedary Camels, Africa , 2014, Emerging infectious diseases.

[107]  Y. Guan,et al.  MERS Coronavirus in Dromedary Camel Herd, Saudi Arabia , 2014, Emerging infectious diseases.

[108]  V. Colizza,et al.  Assessment of the Middle East respiratory syndrome coronavirus (MERS-CoV) epidemic in the Middle East and risk of international spread using a novel maximum likelihood analysis approach. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[109]  Y. Guan,et al.  Seroepidemiology of Middle East respiratory syndrome (MERS) coronavirus in Saudi Arabia (1993) and Australia (2014) and characterisation of assay specificity. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[110]  J. McLellan,et al.  Host Species Restriction of Middle East Respiratory Syndrome Coronavirus through Its Receptor, Dipeptidyl Peptidase 4 , 2014, Journal of Virology.

[111]  Vishwesh P. Mokashi,et al.  Full-Genome Sequence of Human Betacoronavirus 2c Jordan-N3/2012 after Serial Passage in Mammalian Cells , 2014, Genome Announcements.

[112]  R. Baric,et al.  Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution , 2014, Proceedings of the National Academy of Sciences.

[113]  M. Frieman,et al.  Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice , 2014, Vaccine.

[114]  R. Baric,et al.  Rapid generation of a mouse model for Middle East respiratory syndrome , 2014, Proceedings of the National Academy of Sciences.

[115]  Amit Kapoor,et al.  Middle East Respiratory Syndrome Coronavirus Infection in Dromedary Camels in Saudi Arabia , 2014, mBio.

[116]  Shibo Jiang,et al.  Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines , 2014, Vaccine.

[117]  Z. Memish,et al.  Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study , 2014, International Journal of Infectious Diseases.

[118]  Shibo Jiang,et al.  A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines , 2013, PloS one.

[119]  Honglin Chen,et al.  An Animal Model of MERS Produced by Infection of Rhesus Macaques With MERS Coronavirus , 2013, The Journal of infectious diseases.

[120]  Michael G. Katze,et al.  Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques , 2013, Proceedings of the National Academy of Sciences.

[121]  Astrid Gall,et al.  Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study , 2013, The Lancet.

[122]  Y. Guan,et al.  Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[123]  G. Sutter,et al.  Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies , 2013, Journal of Virology.

[124]  Z. Memish,et al.  A family cluster of Middle East Respiratory Syndrome Coronavirus infections related to a likely unrecognized asymptomatic or mild case , 2013, International Journal of Infectious Diseases.

[125]  Z. Memish,et al.  Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study , 2013, The Lancet Infectious Diseases.

[126]  H. Feldmann,et al.  Pneumonia from human coronavirus in a macaque model. , 2013, The New England journal of medicine.

[127]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[128]  Alexander E. Gorbalenya,et al.  Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in Humans , 2012, mBio.

[129]  A. Osterhaus,et al.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.

[130]  R. Couch,et al.  Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus , 2012, PloS one.

[131]  A. Heath,et al.  The first international standard for antibodies to HPV 16. , 2011, Vaccine.

[132]  A. Heath,et al.  Reproducibility of Serologic Assays for Influenza Virus A (H5N1) , 2009, Emerging infectious diseases.

[133]  F. Polack.  Atypical Measles and Enhanced Respiratory Syncytial Virus Disease (ERD) Made Simple , 2007, Pediatric Research.

[134]  T. Butt,et al.  Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia , 2014, Annals of Saudi medicine.

[135]  Malik,et al.  Kinetics of Neutralizing Antibodies in Patients Naturally Infected by H5N1 Virus , 2010, PloS one.

[136]  B. Eaton,et al.  Bats, Civets and the Emergence of SARS , 2007, Current topics in microbiology and immunology.

[137]  V. Fulginiti,et al.  Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. , 1967, JAMA.